No abstract

Background: Multiple myeloma (MM) is a frequent hematologic malignancy. Despite the important advances in treatment strategies during the last decades, the gold standard remains being a proteasome inhibitor (PI)-based induction, followed by autologous stem cell transplant (ASCT). In Latin America (LA) there is great heterogeneity in access to new drugs and ASCT, and there is scarce data regarding patient´s outcomes in the region. Aims: The aim of this study was to describe clinical characteristics and outcomes of MM transplant eligible patients in LA countries. Methods: Retrospective international multicenter cohort study. Unselected consecutive MM transplant-eligible patients diagnosed between 2010 and 2018 from participating centers in Chile, Argentina and Uruguay were included. Data was collected from clinical records in a standardized report form. We analyzed clinical characteristics at diagnosis and frontline therapy outcomes, including ASCT. Transplant-eligible patients were defi ned as fi t patients younger than 66 years old. Response to treatment was defi ned according to current IMWG criteria. Statistical analysis was performed by using STATA 13.